Cytox Ltd.

Cytox Ltd.'s diagnostics and research services are all based on the cell division cycle theory of Alzheimer's pathogenesis. The firm thinks its diagnostic, a blood test biomarker that measures the integrity of the cell cycle G1/S restriction point in peripheral blood lymphocytes, will detect AD in pre-symptomatic stages and that it can predict which patients suffering from mild cognitive impairment will convert to Alzheimer's. Furthermore, Cytox maintains that its lead program, a neuroblastoma assay, can screen compounds for their potential to affect Alzheimer's disease.